Video

Recent Data for PARP Inhibitors in Recurrent Ovarian Cancer

Author(s):

Ritu Salani, MDUrsula A. Matulonis, MD

A detailed discussion focused on recent data on PARP inhibitors in the recurrent ovarian cancer setting.

Related Videos
Ana Christina Garrido-Castro, MD
Jean-Marc Classe, MD, PhD, Nantes Université
Bradley McGregor, MD
Suresh Ramalingam, MD, and Chandler Park, MD
Olivia Aranha, MD, PhD
Michael Iglesia, MD, PhD
Daniel M. Halperin, MD, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Haeseong Park, MD, MPH
Timothy Yap, MBBS, PhD, FRCP
Video 14 - "Key Takeaways in HER2-Mutated NSCLC"
Related Content
Mansoor Raza Mirza, MD
June 7th 2024

Dostarlimab With Carboplatin/Paclitaxel Shows Survival Benefits in dMMR/MSI-H Endometrial Cancer

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Angeles Alvarez Secord, MD, MHSc
June 6th 2024

Mirvetuximab Soravtansine Meets Primary End Point of PICCOLO Trial in FRα-High, Platinum-Sensitive Ovarian Cancer

Stephanie L. Graff, MD, director, Breast Oncology, Lifespan Cancer Institute, associate professor, medicine, Brown University; Reshma L. Mahtani, DO, medical oncologist, Miami Cancer Institute, chief, Breast Medical Oncology, Baptist Health’s Wellness and Medical Complex; Kelly E. McCann, MD, PhD, breast medical oncologist, assistant clinical professor, medicine, the University of California, Los Angeles Health David Geffen School of Medicine; Hope S. Rugo, MD, Winterhof Family Endowed Professor in Breast Cancer, the University of California San Francisco (UCSF), professor, medicine, Division of Hematology and Oncology, director, Breast Oncology, director, Clinical Trials Education, director, Cancer Infusion Services, the UCSF Helen Diller Family Comprehensive Cancer Center
April 11th 2024

Breast Cancer Experts Share Obstacles and Successes as Women in Oncology

Frederik Marmé, MD, PhD, of the University of Heidelberg
June 2nd 2024

Addition of Atezolizumab to Chemotherapy and Bevacizumab Does Not Yield Benefit in Ovarian Cancer

Don S. Dizon, MD, FACP, FASCO, of Lifespan Cancer Institute
June 2nd 2024

Nivolumab/Ipilimumab Bests Nivolumab in Ovarian and Extra-Renal Clear Cell Carcinomas